If you expect knowing the truth to erase the placebo response, the trials don’t support that certainty — openly identified placebos still changed some reported symptoms

You know the treatment has been identified as a placebo, yet the reported symptoms still change. That result can happen without deception, according to randomized open-label placebo studies.

So what do the numbers actually show when nobody hides the placebo? Reports in Pain, Scientific Reports, and JAMA Network Open describe changes in pain, fatigue, distress, and other outcomes.

The record remains mixed. Some trials report meaningful group differences, while others find no added effect or no lasting difference.

Those limits matter. A group average cannot predict whether one reader will respond, and a symptom score does not prove that a disease changed.

Before the sections open, the figures this page stands on — each one carrying its own source.

What an open-label placebo result means

An open-label placebo leaves the reader facing an odd fact. The treatment has been identified as a placebo from the start.

Deception therefore cannot explain the full result. A randomized irritable bowel syndrome trial reported reduced symptom severity and adequate relief at both measured time points.

Knowing about the placebo does not erase every response

The reader may expect full knowledge to cancel any change. Trials across several conditions show that symptoms can still shift after a clearly described placebo.

An updated systematic review and meta-analysis found effects in clinical and non-clinical samples. Effects appeared especially clear in self-reported outcomes.

That wording needs care. It describes an overall pattern across trials, rather than a guarantee for every condition or participant.

Explanation and expectation can shape the result

You may respond differently depending on whether you hear a clear explanation or receive little context. One heat-pain experiment tested that issue directly.

Groups receiving a rationale reported lower pain intensity, with d = 0.43, and lower unpleasantness, with d = 0.49, than the open-label group without that rationale.

A network meta-analysis also found positive treatment expectations important for open-label placebo effects. Expectation formed part of the studied setting.

Response still varied sharply. The figures here show how many participants responded in one analgesia experiment and how pain changed in another.

Those values come from separate studies with different designs. They describe observed groups and should remain tied to those exact experiments.

What the pain numbers show

Pain numbers matter most when the reader wants to know whether a reported change had practical size. Several trials provide direct comparisons.

A chronic low back pain trial reported a 1.5 reduction on composite pain scales in the open-label group. Usual treatment showed 0.2.

Acute pain changed during placebo treatment

The health question looks different during short, induced pain. Healthy adult males reported pain ratings 21% lower during placebo treatment than during no treatment.

Median ratings measured 4.0 during placebo treatment and 5.1 during no treatment. The reported comparison had P = 0.001.

That experiment concerned induced acute pain in healthy adult males. It does not establish the same size of change for chronic illness or another population.

Knee and back pain trials found group differences

A reader living with ongoing pain will care about clinical settings. A knee osteoarthritis trial reported lower daily pain in open-label groups than no treatment.

The knee study reported p = 0.013 and d = 0.64. Two different open-label explanations produced no difference between each other, with p = 0.856 and d = 0.05.

An open-label injection trial for chronic back pain reported relative reduction of 0.61 and Hedges g = 0.45 compared with usual care.

Readers can place several study comparisons side by side here. Each row keeps its own scale, group, and statistical result.

The scales cannot be swapped or merged. A change on one pain measure does not equal the same number on an irritable bowel syndrome scale.

Enough theory. Pull up your own week — the clock below keeps the ledger your body has been keeping anyway.

Symptoms studied beyond pain

If your health question extends beyond pain, you may wonder whether open-label findings do too. Trials have examined fatigue, distress, anxiety, and bowel symptoms.

Irritable bowel syndrome showed greater mean improvement

The reader looking at bowel symptoms gets a direct group comparison.

Mean improvement on the IBS Severity Scoring System reached 90.6 with open-label placebo and 52.3 with no-pill control.

The difference at the 6-week endpoint had P = 0.038. An earlier trial also reported reduced symptom severity and adequate relief at both assessed time points.

Quality of life in that earlier study showed a trend favoring open-label placebo at the 21-day endpoint, with p = .08.

A trend carries less certainty than a significant result.

Cancer-related fatigue improved in two trials

Fatigue can disrupt daily life even when treatment remains unchanged. One cancer-related fatigue trial let usual-treatment participants try open-label placebo for 21-days after the main study.

Those participants reported reductions of 23% in fatigue severity and 35% in fatigue-disrupted quality of life. The percentages describe that group during that study period.

Another trial found significant improvement in cancer-related fatigue on days 15 and 29. Once every participant received open-label placebo, the study found no difference between arms.

Students reported changes during exams

The reader facing stress may notice that researchers also studied healthy students. After a 21-day application during midterm exams, students reported better subjective well-being.

The measured areas included stress, fatigue, and confusion. A separate trial found improved test anxiety and self-management abilities after two weeks compared with a control group.

An imaginary-pill and open-label placebo study also reported a significant group-by-time interaction for test anxiety. That finding concerned anxiety measured in the study setting.

The strongest findings underneath all of this, laid out plainly with their receipts.

Where open-label placebo studies found no added effect

The reader needs the studies that found no extra effect as much as the positive results. Several trials provide that counterweight.

Allergic rhinitis improved across groups

An open-label placebo can coincide with improvement without causing the extra change. In a remote allergic rhinitis trial, symptoms fell across all treatment groups after two weeks.

The open-label placebo added no incremental effect over treatment as usual. Improvement from baseline alone therefore could not separate the placebo condition from the comparison.

A different allergic rhinitis publication described a planned trial of 120 patients across four groups. As a study protocol, it described methods rather than completed results.

One chronic back pain trial found no group differences

A reader with chronic low back pain encounters conflicting findings across trials. A Japanese study found no significant differences between groups at week 3.

The RMDQ result had p = 0.40, the pain-NRS result had p = 0.19, and the TUG result had p = 0.98.

Those outcomes covered disability, pain, and timed movement. The null findings prevent one positive back-pain trial from standing as a universal answer.

Longer placebo use did not improve hot-flush results

The reader may assume that taking a placebo longer should produce more change. A menopausal hot-flush trial did not find a difference between 8 or 4 weeks.

The reported log-transformed score difference measured 0.04, with an interval from − 0.17 to 0.25 and p = 0.73.

That result compares two treatment lengths. It does not by itself determine whether either length differed from every other possible comparison.

The strongest and weakest findings can be viewed together here. The contrast helps keep positive results and null results in the same frame.

Mixed evidence does not make the whole field meaningless. It narrows the claim to specific outcomes, comparison groups, and study periods.

Every section above has roots. Here they are, drawn as a tree — leaves quoted, receipts attached.

You have read enough about minds in general. This one maps yours — drawn live from your answers, with a citation under every claim.

What brain findings can and cannot establish

The open-label placebo question becomes harder when the reader asks what happened inside the brain. A few experiments measured neural activity alongside reported experience.

Responses to angry faces changed after placebo administration

The phrase neural processing can sound like proof of a full mechanism. One experiment found reduced LPP amplitudes to anger expressions across a frontal cluster.

The measured window ran from 1000–6000 ms. Researchers linked that result to processing and evaluation of negative facial expressions after open-label placebo administration.

The measurement shows a difference in recorded activity. It does not establish one complete pathway that explains every clinical response.

Emotional distress tracked with activity in named regions

The reader considering emotional symptoms gets another association rather than a final cause. Reduced emotional distress accompanied activation in several brain areas.

Those areas included the periaqueductal gray, bilateral anterior hippocampi, and anterior cingulate cortex. The report described them as regions known to modulate affective states.

An association between distress and activity cannot show that the measured regions produced every change. The study supports a neural correlate within its own design.

Naloxone changed one analgesia response

A health reader may also encounter claims about the body’s opioid system. One experiment tested open-label nondeceptive placebo analgesia with the opioid antagonist naloxone.

In that study, 40.6% showed a substantial response and 59.4% did not respond. Naloxone blocked the reported open-label placebo analgesia.

This result supports involvement of an opioid-sensitive process in that experiment. It cannot assign one mechanism to fatigue, bowel symptoms, anxiety, and every form of pain.

Remember the note you left? It has been waiting for you.

How long the reported changes lasted

A short change may matter now, while the reader still needs to know whether it lasts. Follow-up findings point in different directions.

One follow-up found no lasting group difference

The reader hoping for durable relief should look beyond the treatment endpoint. A 3-year follow-up examined a 3-week open-label placebo treatment for chronic low back pain.

Across the 3-year period, researchers found no differences in any outcome between groups with and without the open-label treatment.

That finding places a clear boundary around the earlier intervention. A short treatment did not leave a detectable group advantage at that later follow-up.

Another back pain follow-up reported persistent improvement

The same health topic also carries a different long-term report. A 5-year follow-up found that improvements persisted and medication use fell compared with baseline.

Use of pain medication changed from 87% to 38%. The categories included analgesics, which changed from 80% to 31%.

Antidepressant use changed from 24% to 11%, while benzodiazepine use changed from 15% to 5%. These comparisons used each group’s baseline.

Baseline change does not answer the same question as a lasting difference between randomized groups. The two follow-ups therefore support different kinds of statements.

Follow-up design changes the meaning

A reader comparing these reports should first identify the reference point. Some figures compare a later result with baseline, while others compare treatment groups.

Those questions can produce different answers without a numerical contradiction. Persistent improvement within a group can coexist with no later advantage over another group.

Time also changes what the study can claim. Results at two weeks, 21-days, week 3, 6-week, 3-year, and 5-year endpoints remain specific to those assessments.

If any of this pressed on something tender, the help below is real and free, there whenever you need it.

One last move before the close: press this page into a single sentence of your own — the when and the how, decided now.

And to honour the receipts above: here is how this page itself was built, device by device.

If part of your situation reaches past this page, the guides below cover the next step directly.

How to read open-label placebo numbers for one person

The reader now has several numbers, though none can predict one person’s response. These 7 sections show effects that vary by symptom, design, and follow-up.

Start with the comparison group

Your first check should identify what the open-label group faced against it. Studies used no treatment, usual treatment, no-pill control, and other placebo conditions.

A change from baseline answers whether scores moved over time. A between-group difference asks whether they moved more than scores under the chosen comparison.

The allergic rhinitis study shows why this matters. Every group improved, while open-label placebo produced no extra effect over treatment as usual.

Separate self-reports from objective measures

Your next check should identify who or what produced the number. Pain intensity, fatigue, anxiety, and symptom relief often rely on participant reports.

Spine mobility, timed movement, and recorded neural activity answer different questions. They should not be treated as interchangeable proof of one underlying change.

The updated meta-analysis found open-label placebo effects especially when outcomes came from self-reports. That pattern supports symptom experience as a central measured outcome.

Keep averages separate from individual response

Your own response can differ from a study average. The naloxone experiment illustrates that spread because 40.6% responded substantially while 59.4% did not.

A mean can show a group difference even when many participants see little change. It can also hide stronger responses among a smaller part of the group.

Confidence intervals add another boundary. In the spine-surgery trial, worst pain fell by −1.0 point, with a 95% CI from −2.0 to −0.1.

Average daily pain differed by −0.8 point, with a 95% CI from −1.7 to 0.2. That study did not detect a significant average-pain difference.

The direct answer from the full record

The reader’s original puzzle now has a grounded answer. Open-label placebo effects can occur even when participants know they received a placebo.

Randomized trials report changes in pain, bowel symptoms, fatigue, distress, and test anxiety. Some studies also record altered neural measures or lower medication use.

Other trials find no added effect, no significant group difference, or no lasting advantage. Response rates also show that many participants do not improve.

For one reader, the numbers support possibility rather than certainty. The clearest conclusion stays narrow: deception is not required, outcomes vary, and study context shapes the result.

The questions and answers here keep those limits attached to the findings. Each answer separates what a study measured from what it cannot predict.

This is general information about the mind, not therapy or a diagnosis. If things feel hard, please consult a professional. In a crisis, reach a free, confidential crisis hotline right away; findahelpline.com lists one for your country.